# GAA

## Overview
The GAA gene encodes the enzyme acid alpha-glucosidase, a lysosomal glycoside hydrolase crucial for glycogen metabolism. This enzyme is responsible for breaking down glycogen into glucose within lysosomes, facilitating cellular energy homeostasis, particularly in tissues with high glycogen turnover such as skeletal muscle. Acid alpha-glucosidase is categorized as a lysosomal enzyme and is synthesized as a precursor that undergoes post-translational modifications, including glycosylation, to become active in lysosomes. Deficiency in this enzyme due to mutations in the GAA gene leads to glycogen storage disease type II, also known as Pompe disease, characterized by the accumulation of glycogen in lysosomes, resulting in muscle weakness and other systemic symptoms (Hermans2003Twentytwo; Hoefsloot1988Primary). The gene is expressed ubiquitously, reflecting its essential role in cellular metabolism and maintenance (Kroos2012The).

## Structure
The human gene GAA encodes the enzyme acid alpha-glucosidase, which is crucial for glycogen breakdown. The molecular structure of GAA consists of five distinct domains: an N-terminal P-type trefoil domain (N1), a β-sandwich domain (N2), a catalytic (β/α)8 barrel, a proximal β-sandwich domain (C1), and a distal C-terminal β-sandwich domain (C2) (Deming2017The). The catalytic domain, characteristic of family 31 glycoside hydrolases, is a (β/α)8 barrel that contains the active site (Deming2017The). 

The enzyme undergoes extensive post-translational modifications, including N-linked glycosylation and the formation of disulfide bonds, which are crucial for its stability and function (Deming2017The). The N1 domain is stabilized by three disulfide bonds, while the N2 domain exhibits a β-sandwich topology (Deming2017The). 

GAA also features a secondary sugar-binding site located in the N1 domain, 34Å from the active site, which plays a role in binding sugar molecules like maltotriose and isomaltose (Deming2017The). This secondary site suggests a functional role for the P-type trefoil domain as a carbohydrate-binding module, potentially enhancing the enzymatic activity of mature GAA (Deming2017The).

## Function
The GAA gene encodes the enzyme lysosomal acid alpha-glucosidase, which is essential for the degradation of glycogen into glucose within lysosomes. This enzyme plays a critical role in glycogen metabolism by hydrolyzing alpha-1,4 and alpha-1,6 glycosidic linkages in glycogen, maltose, and isomaltose at acidic pH levels (pH 4-5) (Hermans1991Human; Hoefsloot1988Primary). In healthy human cells, the enzyme is synthesized as a precursor in the endoplasmic reticulum, undergoes glycosylation, and is transported to lysosomes where it becomes active through proteolytic processing (Hoefsloot1988Primary).

The enzyme's activity is crucial for maintaining normal cellular energy metabolism, particularly in tissues with high glycogen turnover, such as skeletal muscle (Kroos2012The). The GAA gene is expressed in all cell types, reflecting its role as a housekeeping gene necessary for the renewal of cell and tissue components (Kroos2012The). Deficiency in this enzyme leads to glycogen storage disease type II, also known as Pompe disease, characterized by the accumulation of glycogen in lysosomes, resulting in muscle weakness and other systemic symptoms (Hermans2003Twentytwo; Hoefsloot1988Primary).

## Clinical Significance
Mutations in the GAA gene are responsible for glycogen storage disease type II, also known as Pompe disease. This autosomal recessive disorder is characterized by a deficiency in the enzyme acid alpha-glucosidase, leading to the accumulation of glycogen in lysosomes, which results in muscle weakness and cardiac issues (Kroos2012The; Hermans2003Twentytwo). The disease manifests in various forms, ranging from the severe infantile-onset form, which includes symptoms like cardiomyopathy and respiratory insufficiency, to milder late-onset forms characterized by progressive skeletal muscle weakness (Dardis2018Impact).

The severity of Pompe disease correlates with specific mutations in the GAA gene. For instance, the c.-32-13T>G mutation is common in late-onset cases and affects splicing, leading to reduced enzyme activity (Montalvo2006Mutation; Zampieri2010Splicing). Other mutations, such as nonsense and frameshift mutations, can lead to a complete loss of enzyme function, contributing to the clinical variability observed in patients (Hermans2003Twentytwo). Splicing mutations can also result in severe phenotypes due to significant defects in mRNA processing (Zampieri2010Splicing). These genetic alterations underscore the importance of understanding the genotype-phenotype correlation in managing Pompe disease.

## Interactions
The GAA gene encodes the enzyme acid alpha-glucosidase, which is involved in glycogen metabolism within lysosomes. This enzyme interacts with various proteins that influence its function and stability. One significant interaction is with the pharmacological chaperone 1-deoxynojirimycin (DNJ), which stabilizes and enhances the lysosomal trafficking of multiple mutant forms of GAA. DNJ binds to the enzyme, increasing its stability and activity, particularly in certain missense mutations, by facilitating the trafficking of these mutants to their mature lysosomal forms (Flanagan2009The).

In the context of cellular stress responses, GAA deficiency is associated with increased activity of stress-sensing kinases like IRE1α and PERK, which are part of the unfolded protein response (UPR) pathway. This interaction leads to decreased levels of mature GAA due to proteasomal degradation, highlighting the enzyme's involvement in broader cellular stress mechanisms (SánchezPorras2023From).

Additionally, the enzyme's deficiency impacts pathways involving AMPK and mTORC1, which are master regulators of autophagy. These interactions suggest that GAA plays a role in cellular energy regulation and autophagy, with its deficiency leading to altered activity of these pathways (SánchezPorras2023From).


## References


[1. (Kroos2012The) Marian Kroos, Marianne Hoogeveen‐Westerveld, Ans van der Ploeg, and Arnold J.J. Reuser. The genotype–phenotype correlation in pompe disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 160C(1):59–68, January 2012. URL: http://dx.doi.org/10.1002/ajmg.c.31318, doi:10.1002/ajmg.c.31318. This article has 97 citations.](https://doi.org/10.1002/ajmg.c.31318)

[2. (Montalvo2006Mutation) A.L.E. Montalvo, B. Bembi, M. Donnarumma, M. Filocamo, G. Parenti, M. Rossi, L. Merlini, E. Buratti, P. De Filippi, A. Dardis, M. Stroppiano, G. Ciana, and M.G. Pittis. Mutation profile of thegaa gene in 40 italian patients with late onset glycogen storage disease type ii. Human Mutation, 27(10):999–1006, 2006. URL: http://dx.doi.org/10.1002/humu.20374, doi:10.1002/humu.20374. This article has 103 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20374)

[3. (Flanagan2009The) John J. Flanagan, Barbara Rossi, Katherine Tang, Xiaoyang Wu, Kirsten Mascioli, Francesca Donaudy, Maria Rosaria Tuzzi, Federica Fontana, Maria Vittoria Cubellis, Caterina Porto, Elfrida Benjamin, David J. Lockhart, Kenneth J. Valenzano, Generoso Andria, Giancarlo Parenti, and Hung V. Do. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Human Mutation, 30(12):1683–1692, December 2009. URL: http://dx.doi.org/10.1002/humu.21121, doi:10.1002/humu.21121. This article has 72 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21121)

[4. (SánchezPorras2023From) Valentina Sánchez-Porras, Johana Maria Guevara-Morales, and Olga Yaneth Echeverri-Peña. From acid alpha-glucosidase deficiency to autophagy: understanding the bases of pompe disease. International Journal of Molecular Sciences, 24(15):12481, August 2023. URL: http://dx.doi.org/10.3390/ijms241512481, doi:10.3390/ijms241512481. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241512481)

[5. (Hermans2003Twentytwo) Monique M.P. Hermans, Dik van Leenen, Marian A. Kroos, Clare E. Beesley, Ans T. Van der Ploeg, Hitoshi Sakuraba, Ron Wevers, Wim Kleijer, Helen Michelakakis, Edwin P. Kirk, Janice Fletcher, Nils Bosshard, Lina Basel-Vanagaite, Guy Besley, and Arnold J.J. Reuser. Twenty-two novel mutations in the lysosomal ?-glucosidase gene (gaa) underscore the genotype-phenotype correlation in glycogen storage disease type ii. Human Mutation, 23(1):47–56, 2003. URL: http://dx.doi.org/10.1002/humu.10286, doi:10.1002/humu.10286. This article has 120 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.10286)

[6. (Dardis2018Impact) Andrea Dardis and Emanuele Buratti. Impact, characterization, and rescue of pre-mrna splicing mutations in lysosomal storage disorders. Genes, 9(2):73, February 2018. URL: http://dx.doi.org/10.3390/genes9020073, doi:10.3390/genes9020073. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes9020073)

[7. (Hoefsloot1988Primary) L. H. Hoefsloot, M. Hoogeveen-Westerveld, M. A. Kroos, J. van Beeumen, A. J. Reuser, and B. A. Oostra. Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex. The EMBO Journal, 7(6):1697–1704, June 1988. URL: http://dx.doi.org/10.1002/j.1460-2075.1988.tb02998.x, doi:10.1002/j.1460-2075.1988.tb02998.x. This article has 122 citations.](https://doi.org/10.1002/j.1460-2075.1988.tb02998.x)

[8. (Hermans1991Human) M.M. Hermans, M.A. Kroos, J. van Beeumen, B.A. Oostra, and A.J. Reuser. Human lysosomal alpha-glucosidase. characterization of the catalytic site. Journal of Biological Chemistry, 266(21):13507–13512, July 1991. URL: http://dx.doi.org/10.1016/s0021-9258(18)92727-4, doi:10.1016/s0021-9258(18)92727-4. This article has 124 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)92727-4)

[9. (Zampieri2010Splicing) Stefania Zampieri, Emanuele Buratti, Silvia Dominissini, Anna Lisa Montalvo, Maria Gabriela Pittis, Bruno Bembi, and Andrea Dardis. Splicing mutations in glycogen-storage disease type ii: evaluation of the full spectrum of mutations and their relation to patients’ phenotypes. European Journal of Human Genetics, 19(4):422–431, December 2010. URL: http://dx.doi.org/10.1038/ejhg.2010.188, doi:10.1038/ejhg.2010.188. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2010.188)

10. (Deming2017The) The molecular basis for Pompe disease revealed by the structure of human acid α-glucosidase. This article has 3 citations.